

TECHNICAL SHEET IDYLLA™ NRAS-BRAF MUTATION TEST



The **Idylla™ NRAS-BRAF Mutation Test**, performed on the Biocartis Idylla™ system, is an *in vitro* diagnostic Test for the qualitative detection of 18 mutations in **codons 12, 13, 59, 61, 117, 146** of the *NRAS* gene and 5 mutations in **codon 600** of the *BRAF* gene. The Idylla™ NRAS-BRAF Mutation Test, from **sample-to-result**, starts with formalin-fixed paraffin-embedded (FFPE) human tissue from metastatic colorectal cancers to liberate DNA for subsequent real-time PCR amplification and detection.

FEATURES

NRAS mutation detection

	G12C (c.34G>T)
	G12S (c.34G>A)
Codon 12 (exon 2)	G12D (c.35G>A)
	G12A (c.35G>C)
	G12V (c.35G>T)
Codon 13 (exon 2)	G13D (c.38G>A)
	G13V (c.38G>T)
	G13R (c.37G>C)
Codon 59 (exon 3)	A59T (c.175G>A)
Codon 61 (exon 3)	Q61K (c.181C>A)
	Q61L (c.182A>T)
	Q61R (c.182A>G)
	Q61H (c.183A>C; c.183A>T)
Codon 117 (exon 4)	K117N (c.351G>C; c.351G>T)
Codon 146 (exon 4)	A146T (c.436G>A)
	A146V (c.437C>T)
NRAS Total (acting as Sample Processing Control)	

BRAF mutation detection

Codon 600	BRAF V600E (c.1799T>A; c.1799_1800delinsAA)
	BRAF V600D (c.1799_1800delinsAC)
	BRAF V600K (c.1798_1799delinsAA)
	BRAF V600R (c.1798_1799delinsAG)
BRAF Total (acting as Sample Processing Control)	

Specimen requirements

Sample Type	FFPE tissue sections (5 to 10 µm)
Neoplastic cells	≥10%, if less macrodissection is required
Tissue area	50-600 mm ² (5 µm) 25-300 mm ² (10 µm)

Performance

Analytical Sensitivity	LOD ≤5% for most prevalent NRAS and BRAF mutations
Between Laboratory Reproducibility (600 results at 3 sites)	100% agreement for 10% NRAS G12D 100% agreement for 10% NRAS G12V 100% agreement for 10% NRAS Q61K 100% agreement for 10% NRAS Q61R 100% agreement for 10% BRAF V600E
Between Lot Reproducibility (300 results on 3 lots)	100% agreement for 10% NRAS G12D 100% agreement for 10% NRAS G12V 100% agreement for 10% NRAS Q61K 100% agreement for 10% NRAS Q61R 100% agreement for 10% BRAF V600E

Total turnaround time

Time	120 minutes
------	-------------

ACCURACY - CLINICAL PERFORMANCE EVALUATION

100% and 99.6% overall diagnostic agreement for the *NRAS* and *BRAF* gene, respectively, was obtained during the clinical performance evaluation comparing Idylla™ with a sequencing-based reference method.

100% overall concordance	Reference Method			Total
	BRAF	V600E	No mutation	
Idylla™ NRAS-BRAF Mutation Test	V600E/D	50		50
	No mutation		185	185
	Total	50	185	235

99.6% overall concordance

Reference Method

NRAS		G12A	G12V	G12C	G12D	G12S	G13D	Q61H	Q61K	Q61L	Q61R	No mutation	Total	
Idylla™ NRAS- BRAF Mutation Test	G12A/V	1	4										5	
	G12C			2									2	
	G12D				8							1*	9	
	G12S					0							0	
	G13D						1						1	
	Q61H							1					1	
	Q61K								7				7	
	Q61L									3			3	
	Q61R										6		6	
	No mutation											201	201	
	Total		1	4	2	8	0	1	1	7	3	6	202	235

* ddPCR confirmed the G12D result (<5% allelic frequency)

IDYLLA™ NRAS PUBLICATIONS

Check our website: <https://www.biocartis.com/publications/articles-posters?cat=19> and subscribe to receive our newest publications.



Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and the Idylla trademark and logo are used trademarks owned by Biocartis. Idylla™ platform and Idylla™ NRAS-BRAF Mutation Test are CE-marked IVD's in Europe. Idylla™ is available for sale in EU, USA and some other countries. Please check availability with the local Biocartis sales representative.